(Reuters) – Cheaper versions of one of the most costly and widely used arthritis treatments in the U.S. are likely to fuel further scrutiny of the middlemen that negotiate drug prices for most insured Americans from lawmakers and the federal government, according to healthcare experts. Read full story
Analysis-Launch of arthritis drug biosimilars ramps up US pressure on pricing 'middlemen'
